Tierarztl Prax Ausg G Grosstiere Nutztiere 2024; 52(05): 264-270
DOI: 10.1055/a-2410-1465
Original Article

In vitro capsule or biofilm formation of Streptococcus uberis and bacteriological cure of bovine mastitis

In vitro Kapsel- oder Biofilmbildung von Streptococcus uberis und bakteriologische Heilungsrate klinischer Mastitiden
Yanchao Zhang
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Nicole Wente
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Stefanie Leimbach
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Doris Klocke
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Anne Tellen
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Julia Nitz
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Franziska Nankemann
1   Faculty II, Microbiology, Hannover University of Applied Sciences and Arts, Hannover, Germany
,
Helen Louton
2   Faculty of Agricultural and Environmental Sciences, University of Rostock, Germany
,
Volker Krömker
3   Department of Veterinary and Animal Sciences, Section for Production, Nutrition and Health, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
› Author Affiliations

Dedication

We dedicate this article to Prof. Dr. Kerstin Müller and would like to thank her for her cooperation with our working group.

Abstract

Objective The relationship between the in vitro detected virulence factors biofilm and capsule formation of Streptococcus (S.) uberis isolates of clinical mastitis in dairy cows and the bacteriological cure rate after antibiotic therapy was investigated in order to better understand the importance of these virulence factors for the bacteriological cure rate.

Material and methods A total of 111 clinical mastitis (CM) cases were collected, in which S. uberis was bacteriologically detected. All mastitis cases were treated in accordance with the approval conditions of the antibiotic udder tubes used. Individual cow information including age, number of lactations, current lactation mastitis and antimicrobial treatment received was recorded. The microtiter plate test was used to detect biofilm formation and Anthony capsule staining was used to detect capsular capacity. Statistical analyses were performed to characterize the correlation between in vitro virulence factors and bacteriological cure (BC) rate.

Results 30.5% (n=29) of the S. uberis isolates of bacteriologically cured cases and 34.5% (n=10) of the isolates of bacteriologically non-cured mastitis cases were found to have the ability to produce capsules in vitro. 70.7% (n=58) of the S. uberis isolates from bacteriologically cured mastitis cases had the ability to produce biofilm in vitro, whereas 58.6% (n=17) of the isolates of non-cured mastitis cases showed ability in producing biofilm. No correlation was found between the in vitro ability of S. uberis to form capsules and biofilms and the BC rate after antibiotic treatment of bovine mastitis.

Conclusion(s) The present work has shown that the investigated in vitro virulence factors are not associated with the BC after antibiotic therapy. Further studies on the role of S. uberis virulence factors are needed to complete the missing knowledge on the difficulties in curing S. uberis mastitis.

Clinical relevance This study is of great clinical relevance since it enhances the understanding of the occurrence of BC in S. uberis mastitis cases. The investigated virulence factors are often addressed as possible reasons for therapy failure, although respective scientific studies are missing.

Zusammenfassung

Gegenstand und Ziel Der Zusammenhang zwischen den in vitro nachgewiesenen Virulenzfaktoren Biofilm- und Kapselbildung von Streptococcus (S.) uberis-Isolaten klinischer Mastitiden bei Milchkühen und der bakteriologischen Heilungsrate nach Antibiotikatherapie wurde untersucht, um die Bedeutung dieser Virulenzfaktoren für die bakteriologische Heilungschance besser zu verstehen.

Material und Methoden Einhundertelf S. uberis-Isolate klinischer Mastitiden wurden untersucht. Die Mastitisfälle wurden gemäß den Zulassungsbedingungen für die verwendeten antibiotischen Eutertuben behandelt. Daten der Einzeltiere bezüglich Alter, Anzahl der Laktationen, Mastitisfälle in der aktuellen Laktation und erhaltene antimikrobielle Behandlungen wurden erfasst. Mittels Mikrotiterplatten-Test wurde Biofilmbildung nachgewiesen und zum Nachweis der Kapselbildung der Isolate wurde die Anthony-Kapselfärbung verwendet. In der statistischen Auswertung wurde die Korrelation zwischen in vitro-Virulenzfaktoren und der bakteriologischen Heilungsrate ausgewertet.

Ergebnisse 30,5% (n=29) der S. uberis Isolate aus geheilten Mastitisfällen und 34,5% (n=10) der S. uberis-Isolate, deren Infektionen nicht bakteriologisch geheilt werden konnten, waren in der Lage, in vitro Kapseln zu produzieren. Eine in vitro Biofilmbildung zeigten 70,7% (n=58) der Isolate aus den geheilten Fällen und 58,6% (n=17) der Isolate aus den nicht geheilten Fällen. Weder die untersuchten in vitro-Virulenzfaktoren von S. uberis noch die bekannten Einflussfaktoren auf die bakteriologische Heilung waren in dieser Untersuchung signifikant mit der bakteriologischen Heilung assoziiert.

Schlussfolgerung(en) Da die in vitro untersuchten Virulenzfaktoren nicht mit der bakteriologischen Heilung nach einer Antibiotikatherapie assoziiert sind, sind weitere Studien, die erregerspezifische und tierindividuelle Charakteristika der bakteriologischen Heilung von Mastitiden gegenüberstellen, erforderlich, um die Mechanismen der bakteriologischen Heilung besser zu verstehen. Die pauschale Benennung von Virulenzfaktoren als Ursachen von unzureichenden bakteriologischen Heilungsraten sollte vorsichtiger gehandhabt werden.

Klinische Relevanz Der Zusammenhang zwischen den untersuchten Virulenzfaktoren von S. uberis und unzureichendem Therapieerfolg klinischer Mastitiden konnte in der vorliegenden Studie nicht bestätigt werden.



Publication History

Received: 01 April 2024

Accepted: 25 April 2024

Article published online:
24 October 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Leigh JA. Streptococcus uberis: A permanent barrier to the control of bovine mastitis?. Vet J 1999; 157: 225-238
  • 2 Schmenger A, Krömker V. Characterization, Cure Rates and Associated Risks of Clinical Mastitis in Northern Germany. Vet Sci 2020; 7: 170
  • 3 Ziesch M, Wente N, Zhang Y. et al. Noninferiority trial investigating the efficacy of a nonantibiotic intramammary therapy in the treatment of mild-to-moderate clinical mastitis in dairy cows with longer lasting udder diseases. Vet Pharm & Therapeutics 2018; 41: 11-21
  • 4 Reinoso E. Bovine Mastitis caused by Streptococcus uberis: Virulence factors and biofilm. J Microb Biochem Technol 2017; 9
  • 5 Krömker V, Reinecke F, Paduch JH. et al. Bovine Streptococcus uberis Intramammary Infections and Mastitis. Clin Microbial 2014; 03
  • 6 Pedersen RR, Krömker V, Bjarnsholt T. et al. Biofilm Research in Bovine Mastitis. Front Vet Sci 2021; 8: 656810
  • 7 Apparao MD, Ruegg PL, Lago A. et al. Relationship between in vitro susceptibility test results and treatment outcomes for gram-positive mastitis pathogens following treatment with cephapirin sodium. J Dairy Sci 2009; 92: 2589-2597
  • 8 Klaas IC, Zadoks RN. An update on environmental mastitis: Challenging perceptions. Transbound Emerg Dis 2018; 65: 166-185
  • 9 Todhunter DA, Smith KL, Hogan JS. Environmental Streptococcal Intramammary Infections of the Bovine Mammary Gland. J Dairy Sci 1995; 78: 2366-2374
  • 10 Bramley AJ, Dodd FH. Reviews of the progress of Dairy Science: Mastitis control – progress and prospects. J Dairy Res 1984; 51: 481-512
  • 11 Smith KL. Suggested interpretation of mastitis terminology. Bulletin-International Dairy Federation. 1999: 3-26
  • 12 Zadoks RN, Tikofsky LL, Boor KJ. Ribotyping of Streptococcus uberis from a dairy’s environment, bovine feces and milk. Vet Microbiol 2005; 109: 257-265
  • 13 Wente N, Klocke D, Paduch JH. et al. Associations between Streptococcus uberis strains from the animal environment and clinical bovine mastitis cases. J Dairy Sci 2019; 102: 9360-9369
  • 14 Bolte J, Zhang Y, Wente N. et al. In Vitro Susceptibility of Mastitis Pathogens Isolated from Clinical Mastitis Cases on Northern German Dairy Farms. Vet Sci 2020; 7: 10
  • 15 Almeida RA, Oliver SP. Antiphagocytic Effect of the Capsule of Streptococcus uberis. J Vet Med. Series B 1993; 40: 707-714
  • 16 Field TR, Ward PN, Pedersen LH. et al. The Hyaluronic Acid Capsule of Streptococcus uberis is not required for the development of infection and clinical mastitis. Infect Immun 2003; 71: 132-139
  • 17 Varhimo E, Varmanen P, Fallarero A. et al. Alpha- and β-casein components of host milk induce biofilm formation in the mastitis bacterium Streptococcus uberis . Vet Microbiol 2011; 149: 381-389
  • 18 Magagula S, Petzer IM, Famuyide IM. et al. Biofilm expression and antimicrobial resistance patterns of Streptococcus uberis isolated from milk samples of dairy cows in South Africa. J Dairy Res 2023; 90: 42-46
  • 19 Melchior MB, Vaarkamp H, Fink-Gremmels J. Biofilms: A role in recurrent mastitis infections. The Veterinary Journal 2006; 171: 398-407
  • 20 Schönborn S, Wente N, Paduch JH. et al. In vitro ability of mastitis causing pathogens to form biofilms. J Dairy Res 2017; 84: 198-201
  • 21 Wente N, Grieger AS, Klocke D. et al. Recurrent mastitis–persistent or new infections?. Vet Microbiol 2020; 244: 108682
  • 22 Lubbers BV. Clinical and Laboratory Standards Institute, Hrsg. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. 4th edition, VET08. 2018
  • 23 Preine F, Schmenger A, Leon L. et al. Status quo und Perspektiven der lokalen antibiotischen Mastitisbehandlung: eine Umfrage unter Landwirten in Deutschland. Der Praktische Tierarzt. 2022 103. 1258-1268
  • 24 German Veterinary Medical Association. Leitlinien zur Entnahme von Milchproben unter Antiseptischen Bedingungen und Isolierung und Identifizierung von Mastitiserregern. In Guidelines for Aseptic Milk Sampling and Guidelines to Isolate and Identify Mastitis Pathogens, 2nd ed.; German Veterinary Medical Association: Gießen, Germany, 2009; Available online https://www.dvg.net/desinfektion/leitlinien-zur-entnahme-von-milchproben/ (accessed on 17 June 2020)
  • 25 Anthony EE. A Note on Capsule Staining. Science 1931; 73: 319-320
  • 26 Bose S, Khodke M, Basak S. et al. Detection of Biofilm Producing Staphylococci: Need of the Hour. J Clin Diagn Res 2009; 3: 1915-1920
  • 27 Kaczorek E, Małaczewska J, Wójcik R. et al. Biofilm production and other virulence factors in Streptococcus spp. isolated from clinical cases of bovine mastitis in Poland. BMC Vet Res 2017; 13: 398
  • 28 Fessia AS, Odierno LM. Potential factors involved in the early pathogenesis of Streptococcus uberis mastitis: a review. Folia Microbiol 2021; 66: 509-523
  • 29 Abureema S. Characterisation of Streptococcus uberis from bovine milk. 2013
  • 30 Ziesch M, Krömker V. Factors influencing bacteriological cure after antibiotic therapy of clinical mastitis. Milchwissenschaft – Milk Sci Int 2016; 69: 7